natgillin/translations-raw huggingface dataset:
A biotic and an allergen for use as claimed in Claim 1 wherein said biotic and allergen are to be administered in two different formulations. 
Probiotik i alergen hrane za upotrebu prema patentnom zahtjevu 1 naznačen time što se spomenuti probiotik i alergen hrane primenjuju u dvije različite formulacije.
and R2 are independently of one another hydrogen, fluorine, chlorine, a methoxy group; 
i R2 su međusobno neovisno vodik, fluor, klor, metoksi skupina;
is hydrogen, fluorine, chlorine or a methoxy group, 
je vodik, fluor, klor ili metoksi skupina;
and their salts, solvates or salts of solvates. 
i njihove soli, solvati ili soli solvata.
lung diseases, which coincide with inflammatory, allergic and/or proliferative, processes, 
bolesti pluća, koje se poklapaju s upalnim, alergijskim i/ili proliferativnim procesima,
dermatological diseases, which coincide with inflammatory, allergic and/or proliferative processes, 
dermatoloških bolesti, koje se poklapaju s upalnim, alergijskim i/ili proliferativnim procesima,
kidney diseases, which coincide with inflammatory, allergic and/or proliferative processes, 
bolesti bubrega, koje se poklapaju s upalnim, alergijskim i/ili proliferativnim procesima,
eye diseases, which coincide with inflammatory, allergic and/or proliferative processes, 
proktoloških bolesti, koje se poklapaju s upalnim, alergijskim i/ili proliferativnim procesima,
neurological diseases, which coincide with inflammatory, allergic and/or proliferative processes, 
bolesti oka, koje se poklapaju s upalnim, alergijskim i/ili proliferativnim procesima,
(xiii) blood diseases, which coincide with inflammatory, allergic and/or proliferative processes, 
bolesti područja uha-grla-nosa, koje se poklapaju s upalnim, alergijskim i/ili proliferativnim procesima,
tumor diseases, which coincide with inflammatory and/or proliferative processes, 
tumorskih bolesti, koje se poklapaju s upalnim i/ili proliferativnim procesima,
endocrine diseases, which coincide with inflammatory, allergic and/or proliferative processes, 
endokrinih bolesti, koje se poklapaju s upalnim, alergijskim i/ili proliferativnim procesima,
emesis, which coincide with inflammatory, allergic and/or proliferative processes, 
emeza, koje se poklapaju s upalnim, alergijskim i/ili proliferativnim procesima,
pains of inflammatory origins, 
bolova upalnog podrijetla,
other different stages of diseases selected from diabetes type I (insulin-dependent diabetes), osteoarthritis, Guillain-Barre syndrome, restenoses after percutaneous transluminal angioplasty, Alzheimer's disease, acute and chronic pain, arteriosclerosis, reperfusion injury, congestive heart failure, myocardial infarction, thermal injury, multiple organ injury secondary to trauma, acute purulent meningitis, necrotizing enterocolitis and syndromes associated with hemodialysis, leukopheresis, and granulocyte transfusion. 
drugih različitih faza bolesti koje su odabrane od dijabetesa tip I (dijabetes ovisan o inzulinu), osteoartritisa, sindroma Guillain-Barre, restenoza poslije perkutane transluminalne angioplastike, Alzheimerove bolesti, akutnog i kroničnog bola, arterioskleroze, reperfuzijske bolesti, kongestivnog zatajenja srca, infarkta miokarda, termičke ozljede, višestruke ozljede organa kao posljedice traume, akutne purulentnog meningitisa, nekrotizirajućeg enterokolitisa i sindroma povezanih s hemodijalizom, leukaferezom, te transfuzijom granulocita.
Process for the manufacture of the compounds of general formula I according to claim 1, wherein the following steps are performed: step a): step b): wherein all residues have the definitions as given in claim 1 and R is C1-C4-alkyl and Met means alkalimetals, alkaline earth metals, aluminium, copper, silicon or tin. 
Postupak za proizvodnju spojeva prema općoj formuli I prema zahtjevu 1, naznačen time da se provode slijedeći koraci: korak a): [image] [image] [image] pri čemu svi ostatci imaju definicije kako je navedeno u zahtjevu 1 i R je C1-C4-alkil i Met predstavlja alkalijske metale, zemno alkalijske metale, aluminij, bakar, silicij ili kositar.
Process step a) according to claim 7 for the manufacture of intermediates of general formula IV, characterized in that benzaldehydes of general formula II are reacted with substituted quinolone amines of formula III to imines of general formula IV in the presence of Lewis acids and/or under acidic conditions, wherein R1, R2, R3 and R4 have the meanings that are defined in claim 1 and R is C1-C4-alkyl. 
Korak a) postupka prema zahtjevu 7 koji je za proizvodnju intermedijera s općom formulom IV, naznačen time da benzaldehidi s općom formulom II reagiraju sa supstituiranim kinolon aminima s formulom III u imine s općom formulom IV u prisutnosti Lewisovih kiselina i/ili u kiselim uvjetima, [image] pri čemu R1, R2, R3 i R4 imaju značenja koja su definirana u zahtjevu 1 i R je C1-C4-alkil.
Process step b) according to claim 7 for the manufacture of intermediates of general formula VI, characterized in that metallated trifluoroepoxipropane V, optionally being in its enantiomerically pure form, is reacted with imines of formula IV at low temperatures to yield epoxides of general formula VI wherein R1, R2, R3 and R4 have the meanings that are defined in claim 1 and optionally subsequently a separation of diastereoisomers is performed. 
Korak b) postupka prema zahtjevu 7 koji je za proizvodnju intermedijera s općom formulom VI, naznačen time da metalirani trifluoroepoksipropan V, koji je proizvoljno u njegovom enantiomerno čistom obliku, reagira s iminima s formulom IV na niskim temperaturama da se dobiju epoksidi s općom formulom VI [image] pri čemu R1, R2, R3 i R4 imaju značenja koja su definirana u zahtjevu 1 i proizvoljno se naknadno provodi odvajanje dijastereoizomera.
Compounds of general formula VI according to claim 11, in form of a racemic mixture or as enantiomerically pure isomer. 
Spojevi opće formule VI prema zahtjevu 9, [image] u obliku racemske smjese ili kao enantiomerno čisti izomer.
Process step c) according to claim 12 for the manufacture of compounds of general formula I, characterized in that ketones of type (IX) optionally in its enantiomerically pure form can be condensed with substituted amino quinolones of type (III) to imines and subsequently or simultaneously reduced to yield compounds formula I wherein R1, R2, R3, R4 and R5 have the meanings that are indicated in claim 1 and R as defined in claim 8 and optionally subsequently a separation of diastereoisomers may be performed. 
Korak c) postupka prema zahtjevu 12 koji je za proizvodnju spojeva opće formule I, naznačen time da ketoni vrste (IX) proizvoljno u njihovom enantiomerno čistom obliku mogu biti kondenzirani sa supstituiranim amino kinolonima vrste (III) u imine i naknadno ili istovremeno mogu biti reducirani da se dobiju spojevi formule I [image] pri čemu R1, R2, R3, R4 i R5 imaju značenja koja su navedena u zahtjevu 1 i R kako je definirano u zahtjevu 8 i proizvoljno se naknadno može provesti odvajanje dijastereoizomera.
• a muscarinic receptor antagonist (for example a M1, M2 or M3 antagonist, such as a selective M3 antagonist) such as ipratropium bromide, tiotropium bromide, oxitropium bromide, pirenzepine or telenzepine; 
• antagonist muskarinskog receptora (na primjer M1, M2 ili M3 antagonist, kao što je selektivni antagonist M3) kao što su ipratropij bromid, tiotropij bromid, oksitropij bromid, pirenzepin ili telenzepin;
Use according to claim 15, wherein the dermatological disease is selected from atopic dermatitis, all forms of eczema, rashes of any origin or dermatoses, psoriasis and parapsoriasis groups, pityriasis rubra pilaris, bullous dermatoses, diseases of the lichenoid group, pruritis, seborrheal eczema, rosacea group, erythema exudativum multiforme, balanitis, vulvitis, manifestation of vascular diseases, hair loss, cutaneous lymphoma. 
Upotreba prema zahtjevu 15, naznačena time da je dermatološka bolest odabrana od atopijskog dermatitisa, svih oblika ekcema, osipa bilo kojeg podrijetla ili dermatoza, psorijaze i skupina parapsorijaze, Pityriasis rubra pilaris, buloznih dermatoza, bolesti iz skupine lišajeva, svraba, seboreičnog ekcema, skupine rozacea, eritema eksudativum multiforme, balanitisa, vulvitisa, manifestacija bolesti krvnih žila, gubitka kose, kožnog limfoma.
A pharmaceutical composition comprising suitable pharmaceutical excipients and also comprising a human in vivo clinical effective amount of a recombinant human growth hormone (rhGH) PEGylated prodrug conjugate, wherein PEG is linked to rhGH via a self hydrolysable (autocleavage) transient linker; said prodrug conjugate is characterized in that: 
Farmaceutski sastav koji obuhvaća prikladna pomoćna sredstva i također sadrži za čovjeka klinički učinkovitu količinu in vivo rekombinantnog ljudskog hormona rasta (rhGH)-PEGilirani predlijek-konjugata, pri čemu je PEG povezan s rhGH preko samohidrolizirajućeg (samocijepajućeg) prijelaznog poveznog elementa; gdje je navedeni predlijek-konjugat naznačen time, da:
(2): the linker autohydrolysis rate is such that the in vivo half-life is from 10 hours to 600 hours which is measured by intravenously injecting into rats the conjugate, followed by taking blood samples at time intervals, preparing plasma and analyzing hGH using ELISA; and wherein the PEGylated prodrug conjugate has the chemical structure (A): wherein 
brzina samohidrolize poveznog elementa je takva, da je poluživot in vivo od 10 sati do 600 sati, što se mjeri pomoću intravenozne injekcije konjugata u štakore, a nakon toga slijedi uzimanje uzoraka krvi u vremenskim intervalima, pripravljanje plazme i hGH-analiza uporabom ELISA; i pritom PEGilirani predlijek-konjugat ima sljedeću kemijsku formulu (A):
PEG represents the pegylation residue attached to the transient linker; 
PEG predstavlja pegilacijski ostatak priključen na prijelazni povezni element;
The pharmaceutical composition of claim 1, wherein the autohydrolysis rate is such that the in vivo half life is up to 5 times shorter than the corresponding hGH PEGylated prodrug conjugate's in vitro half-life. 
Farmaceutski sastav prema zahtjevu 1, naznačen time, da brzina samohidrolize poveznog elementa je takva, da je poluživot in vivo do pet puta kraći nego odgovarajući poluživot in vitro od hGH-PEGiliranog predlijek-konjugata.
The pharmaceutical composition of claim 2, wherein the in vivo half life is up to 3 times shorter than the corresponding hGH PEGylated prodrug conjugate's in vitro half-life. 
Farmaceutski sastav prema zahtjevu 2, naznačen time, da je poluživot in vivo do tri puta kraći nego odgovarajući poluživot in vitro od hGH-PEGiliranog predlijek-konjugata.
The pharmaceutical composition of any of claims 1 to 4, wherein the composition is a composition for subcutaneous administration, intramuscular administration or intravenous injection. 
Farmaceutski sastav prema bilo kojem od zahtjeva 1 do 4, naznačen time, da sastav je pripravak za subkutanu primjenu, intramuskularnu primjenu ili intravenoznu injekciju.
The pharmaceutical composition of any of claims 1 to 5, wherein the PEGylated prodrug has a total PEG load per growth hormone molecule that amounts to at least 25 kDa. 
Farmaceutski sastav prema bilo kojem od zahtjeva 1 do 5, naznačen time, da PEGilirani predlijek ima ukupno PEG-punjenje u količini do najmanje 25 kDa po molekuli hormona rasta.
The pharmaceutical composition of any of claims 1 to 6, wherein the partial structure of formula (I) within structure (A) of claim 1, which is is selected from the group consisting of: 
Farmaceutski sastav prema bilo kojem od zahtjeva 1 do 6, naznačen time, da je djelomična struktura od sljedeće formule (I) koja je unutar strukture (A) prema zahtjevu 1: [image] odabrana iz skupine koju čine:
The pharmaceutical composition of any of claims 1 to 7, wherein the partial structure of formula (II) within structure (A) of claim 1, which is is selected from the group consisting of: 
Farmaceutski sastav prema bilo kojem od zahtjeva 1 do 7, naznačen time, da je djelomična struktura od sljedeće formule (II) koja je unutar strukture (A) prema zahtjevu 1: [image] odabrana iz skupine koju čine:
A prodrug selected from the group consisting of wherein m is an integer from 200 to 250 and n is an integer from 100 to125; wherein n is an integer from 400 to 500; wherein n is an integer from 400 to 500; and wherein n is an integer from 400 to 500. 
Predlijek, naznačen time, da je odabran iz skupine koju čine: [image] pri čemu je m cijeli broj od 200 do 250, dok je n cijeli broj od 100 do 125; [image] gdje n je cijeli broj od 400 do 500; [image] dok n je cijeli broj od 400 do 500; i [image] gdje n je cijeli broj od 400 do 500.
A pharmaceutically acceptable composition of a parasiticidally effective, subtoxic amount of imidacloprid from 0.01 mg/kg body weight to 30 mg/kg body weight for use in a method to eliminate blood-sucking or consuming parasites on mammals, wherein imidacloprid is the only parasiticidal agent present in the pharmaceutical composition and wherein the parasites are ectoparasites and wherein the method comprises orally delivering said composition to said mammals. 
Farmaceutski prihvatljiv pripravak parazitocidno djelotvorne, subtoksične količine imidakloprida od 0,01 mg/kg tjelesne težine do 30 mg/kg tjelesne težine, namijenjen upotrebi u postupku uklanjanja parazita koji sišu ili konzumiraju krv na sisavcima, naznačen time što je imidakloprid jedini parazitocid prisutan u farmaceutskom pripravku, što su paraziti ektoparaziti, te što se postupak sastoji u oralnom unosu navedenog pripravka u navedene sisavce.
The composition for use according to Claim 1, wherein the composition is formulated as a chewable soft treat. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je pripravak formuliran kao meka poslastica pogodna za žvakanje.
The composition for use according to Claim 1, wherein the parasiticidally effective amount kills adult fleas. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što parazitocidno djelotvorna količina ubija odrasle buhe.
The composition for use according to Claim 1, wherein the parasiticidally effective amount kills adult ticks or tick nymphs. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što parazitocidno djelotvorna količina ubija odrasle krpelje ili nimfe krpelja.
The composition for use according to Claim 1, wherein the parasiticidally effective amount kills blood-sucking or consuming helminthes. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što parazitocidno djelotvorna količina ubija helminte koji sišu ili konzumiraju krv.
The composition for use according to Claim 1, wherein the parasiticidally effective amount kills blood-sucking or consuming scabies. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što parazitocidno djelotvorna količina ubija šugarce koji sišu ili konzumiraju krv.
The composition for use according to Claim 1, wherein the parasiticidally effective amount sufficient to prevent reinfestation of a mammal with fleas. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je parazitocidno djelotvorna količina dovoljna za sprječavanje reinfestacije sisavca buhama.
The composition for use according to Claim 1, wherein the parasiticidally effective amount sufficient to prevent reinfestation of a mammal with ticks. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je parazitocidno djelotvorna količina dovoljna za sprječavanje reinfestacije sisavca krpeljima.
is phenyl which is unfused or fused with arene, heteroarene or R8A; R8A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; is heteroaryl which is unfused or fused with arene, heteroarene or R9A; R9A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; 
je fenil koji je nekondenziran ili kondenziran s arenom, heteroarenom ili R8A; R8A je cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; je heteroaril koji je nekondenziran ili kondenziran s arenom, heteroarenom ili R9A; R9A je cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken;
is alkyl which is unsubstituted or substituted with R36; 
je alkil koji je nesupstituiran ili supstituiran s R36;
wherein the alkyl, alkenyl, alkynyl are unsubstituted or substituted with OCH3; and 
pri čemu su alkil, alkenil, alkinil nesupstituirani ili supstituirani s OCH3; a
is heteroaryl or R48A; R48A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; is C3-C6-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R49A; R49A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; 
je heteroaril ili R48A; R48A je cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; R49 je C3-C6-cikloalkil ili C4-C6-cikloalkenil, od kojih svaki ima jednu ili dvije CH2 skupine nezamijenjene ili zamijenjene s neovisno odabranim O, C(O), CNOH, CNOCH3, S, S(O), SO2 ili NH s jednom ili dvije CH skupine nezamijenjene ili zamijenjene s N i od kojih je svaka nekondenzirana ili kondenzirana s arenom, heteroarenom ili R49A; R49A je cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken;
The compound of claim 2, or therapeutically acceptable salt thereof, wherein the compound is chosen from: 
Spoj u skladu s patentnim zahtjevom 2, ili njegova terapeutski prihvatljiva sol, naznačen time, da je spoj odabran iz skupine koju čine:
A composition for use in treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, a lymphoid malignancy of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer, said composition comprising an excipient and a therapeutically effective amount of the compound or therapeutically acceptable salt of any one of claims 1-13 . 
Spoj za uporabu u liječenju bolesti iz skupine koju čine rak mokraćnog mjehura, rak mozga, rak dojke, rak koštane srži, cervikalni rak, kronična limfocitna leukemija, rak debelog crijeva, rak jednjaka, rak jetre, limfoblastična leukemija, folikularni limfomi, limfna malignost uzorkovana T-stanicama ili B-stanicama, melanom, mijeloične leukemije, mijeloma, oralni karcinom, rak jajnika, rak ne-malih stanica pluća, rak prostate, rak malih stanica pluća ili rak slezene, naznačen time, da navedeni pripravak sadržava pomoćno sredstvo i terapeutski djelotvornu količinu spoja ili terapeutski prihvatljive soli u skladu s bilo kojim od patentnih zahtjeva 1 do 13.
The compound or therapeutically acceptable salt of any one of claims 1-13 for use in treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, a lymphoid malignancy of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer in a patient. 
Spoj ili terapeutski prihvatljiva sol u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time, da se rabi u liječenju sljedećih bolesti kod pacijenta: rak mokraćnog mjehura, rak mozga, rak dojke, rak koštane srži, cervikalni rak, kronična limfocitna leukemija, rak debelog crijeva, rak jednjaka, rak jetre, limfoblastična leukemija, folikularni limfomi, limfna malignost uzrokovana T-stanicama ili B-stanicama, melanom, mijeloične leukemije, mijeloma, oralni karcinom, rak jajnika, rak ne-malih stanica pluća, rak prostate, rak malih stanica pluća ili rak slezene.
a mixture of water with acetone or an aliphatic ketone of 4-5 carbon atoms, and 
smjese vode s acetonom ili alifatskim ketonom s 4-5 atoma ugljika, i
acetone, an aliphatic ketone of 4-5 carbon atoms, or a mixture thereof; or 
acetona, alifatskog ketona s 4-5 atoma ugljika, ili njihove smjese; ili
the solid salt containing an undesired amount of the impurities having genotoxic effect and/or of the residual solvents known as potential precursors thereof, is slurried with a solvent selected from: water, 
čvrsta sol koja sadrži neželjenu količinu nečistoća koje imaju genotoksični učinak i/ili preostalih otapala poznatih kao njihovi mogući preteče razmulji se otapalom koje se bira između: vode,
acetone, an aliphatic ketone of 4-5 carbon atoms or a mixture thereof; or 
acetona, alifatskog ketona s 4-5 atoma ugljika ili njihova smjesa; ili
the solid salt containing an undesired amount of the impurities having genotoxic effect and/or of the residual solvents known as potential precursors thereof is exposed to air stream having high degree of relative humidity at a temperature and for a time sufficient to allow the removal of the above said impurities having genotoxic effect and/or of the residual solvents known as potential precursors thereof; and, 
čvrsta sol koja sadrži neželjenu količinu nečistoća koje imaju genotoksični učinak i/ili preostalih otapala poznatih kao njihovi mogući preteče se izloži struji zraka s visokim stupnjem relativne vlage, na temperaturi i u vremenu dovoljnom da se omogući uklanjanje gore navedenih nečistoća koje imaju genotoksični učinak i/ili preostalih otapala poznatih kao njihovi mogući preteče; i,
or a mixture thereof with the crystalline anhydrous polymorph form A, 
ili njegova smjesa s kristalnim bezvodnim polimorfnim oblikom A,
said hemihydrate pseudopolymorph form H or the above said mixture thereof is wholly converted into the crystalline anhydrous polymorph form A by removal of the crystallization water on heating. 
navedeni hemihidratni pseudopolimorfni oblik H ili gore navedenu njegovu smjesa se u potpunosti prevodi u kristalni bezvodni polimorfni oblik A uklanjanjem kristalizacijske vode prilikom grijanja.
a mixture of water with acetone or an aliphatic ketone of 4-5 carbon atoms; or 
smjese vode s acetonom ili alifatskim ketonom s 4-5 atoma ugljika; ili
the solid salt containing an undesidered amount of the impurities having genotoxic effect and/or of the residual solvents known as potential precursors thereof, is slurried with a solvent selected from: water, 
čvrsta sol koja sadrži neželjenu količinu nečistoća koje imaju genotoksični učinak i/ili preostalih otapala poznatih kao njihovi mogući preteče razmulji se otapalom koje se bira između: vode,
the solid salt containing an undesidered amount of the impurities having genotoxic effect and/or of the residual solvents known as potential precursors thereof is exposed to air stream having high degree of relative humidity at a temperature and for a time sufficient to allow the removal of the above said impurities having genotoxic effect and/or of the residual solvents known as potential precursors thereof; 
čvrsta sol koja sadrži neželjenu količinu nečistoća koje imaju genotoksični učinak i/ili preostalih otapala poznatih kao njihovi mogući preteče se izloži struji zraka s visokim stupnjem relativne vlage, na temperaturi i u vremenu dovoljnom da se omogući uklanjanje gore navedenih nečistoća koje imaju genotoksični učinak i/ili preostalih otapala poznatih kao njihovi mogući preteče;
or a mixture of said crystalline hemihydrate pseudopolymorph form H with the crystalline anhydrous polymorph form A; and 
ili smjesa navedenog kristalnog hemihidratnog pseudopolimorfnog oblika H s kristalnim bezvodnim polimorfnim oblikom A; i
said hemihydrate pseudopolymorph H or the above said mixture thereof is wholly converted into the crystalline anhydrous polymorph form A by removal of the crystallization water on heating. 
navedeni hemihidrat pseudopolimorf H ili gore navedenu njegovu smjesa se u potpunosti prevede u kristalni bezvodni polimorfni oblik A uklanjanjem kristalizacijske vode prilikom grijanja.